Tempus connects molecular testing, clinical data and AI research

Tempus combines molecular testing, clinical information and AI software for precision medicine and research. Its products serve different jobs: clinicians order and interpret tests, life sciences teams investigate research questions, and institutions use software to identify gaps in care pathways. Understanding those separate routes is essential before treating Tempus as a single AI subscription.

01 / ProductTesting and software sit around the same information problem

The oncology portfolio spans hereditary risk testing, tumor profiling and monitoring, alongside algorithmic and biomarker offerings. That breadth matters because molecular information is not one interchangeable input. A specimen, an assay result and a longitudinal clinical record describe different aspects of a patient. A team evaluating Tempus should first name the question it needs to answer and then identify the relevant evidence type.

Tempus Hub is the provider-facing place to order tests, follow order status and retrieve results. It provides a practical entry point into the testing relationship. The value of this layer is coordination: an analysis can be scientifically useful yet operationally delayed if specimen status, access or reporting is disconnected from the clinician responsible for the next step.

Tempus One adds a generative AI interface for providers and researchers. The company describes asking questions about molecular and clinical information and constructing research cohorts. One should therefore be understood as an interface to relevant information and workflows, not as a substitute for the underlying assay, evidence or professional interpretation.

Tempus Next focuses on care pathway intelligence and trial workflows. Its published areas include identifying potentially eligible patients, tracking care gaps and following program activity. This is a different unit of work from producing an individual laboratory result: it asks an institution to connect data with responsibility for follow-up.

02 / AudienceChoose the clinical or research route before choosing an interface

A life sciences research team may want a cohort with particular molecular characteristics and sufficiently complete follow-up data. A provider may instead need a testing workflow that fits the practice and returns accessible results. Both use clinical information, but they do not have the same contract, permissions, users or success criteria. Buying access for one purpose should not be assumed to establish rights for another.

The life sciences platform describes research, clinical development and commercialization use cases. It is most relevant when access to suitable real-world data is a meaningful constraint on a specific scientific question. Before discussing the AI layer, ask whether the dataset has the populations, time periods and endpoints the study needs. A large record count cannot answer those questions.

For readers comparing approaches, Abridge addresses a different healthcare information task: producing reviewable clinical documentation from encounters. Databricks illustrates the broader data-platform layer on which an organization might organize its own analytics. The comparison is about where the needed evidence and workflow come from: acquiring access to a specialized healthcare offering differs from building general data infrastructure.

03 / WorkflowA proposed cohort study begins with definitions and provenance

Consider a proposed research evaluation involving a molecularly defined oncology cohort. Write down the research question before opening a conversational interface. Specify which measurement defines inclusion, the relevant treatment period and what counts as observable follow-up. This creates a reference against which a generated query or cohort can be checked, including by colleagues who did not write the initial prompt.

Use an approved environment and authorized data to construct the cohort. Tempus One’s researcher description includes cohort definition and inspection of unstructured source details. In this proposed workflow, compare a small selection of retrieved records with the intended criteria. A phrase such as prior therapy may refer to an actual administration, an order, a recommendation or historical text; treating those as equivalent changes the study.

Next, examine missingness before interpreting a pattern. Determine which fields are systematically absent and whether the absence differs across subgroups or time. A model can summarize the available information coherently while overlooking that a clinically meaningful event occurred outside the captured network. The appropriate response is to qualify the analysis and, where feasible, redesign the question around observable evidence.

Separate exploratory queries from the final analysis specification. An analyst might try several cohort definitions while learning how the data are represented. Keep those experiments visible, then freeze the definition used for the reported result. Otherwise, a later colleague may reproduce the same conversational request but receive a different population after a data refresh or an apparently small wording change.

Have a second researcher review the cohort logic and a sample of source-supported extractions. Record disagreements by type: population eligibility, event timing, source interpretation or missing information. This is more useful than a single satisfaction score because the remedies differ. A query error needs a different response from a source record that never contained the desired information.

Finally, package the result with its cohort version, extraction date and evidence limitations. The proposed output is a defensible research artifact, not a claim that Tempus has validated the study design. The same discipline helps distinguish an exploratory signal worth investigating from evidence strong enough to support a consequential scientific or operational decision.

04 / PricingTesting costs and research agreements are separate questions

The public pages reviewed do not establish a single numerical subscription covering the portfolio. A testing relationship, institutional software deployment and research-data arrangement have materially different scopes. Treating a patient assistance policy as a data-platform price would mix unrelated commercial units and give a misleading impression of what an organization can purchase.

For a research proposal, identify the covered data, permitted analyses, refresh cadence and any requested support before comparing cost. For a provider deployment, define the actual testing and software workflow. These are planning questions, not asserted Tempus fees. The useful budget is the amount required for the specified job, including the organization’s own data review and integration effort.

05 / DistinctionsThe connection between evidence and action is the distinction

Tempus is distinctive in bringing testing, data and workflow software into one company’s offer. That does not mean every component is required in every deployment. It means a buyer can ask how information moves between those components and whether that relationship removes a real bottleneck, such as locating a result, constructing an eligible cohort or assigning follow-up work.

The clinician-facing and research-facing versions of One make that distinction especially clear. Similar language interfaces can serve very different evidence needs. A researcher may need a cohort definition that can be audited across many records; a clinician may need context about an individual result. The interface should preserve those differences rather than make every answer look equally authoritative.

Next also changes the evaluation boundary. A dashboard showing a potential care gap is not itself a completed intervention. The institution needs an owner, a way to resolve duplicates or outdated information, and a record of what happened next. This is an operational inference from the product’s stated role, not an assertion about performance in an untested deployment.

06 / QuestionsData coverage and intended use require product-level answers

What does the research population actually represent?

Ask for a description of how the relevant cohort enters the dataset, what follow-up is observable and how variables are derived. Availability of a molecular result does not establish representative sampling. A study can be useful within a defined population while remaining unsuitable for a broader claim about all patients with the disease.

Which source supports an AI-generated answer?

Inspect the specific laboratory result, excerpt or research field underlying an answer and distinguish it from interpretation. A concise response can hide a mixture of recent and historical information. For a meaningful evaluation, keep the question, available context and source-backed answer together so reviewers can identify where an unsupported inference entered the chain.

What is actually accessible to this organization?

Hub provides an access-request route, while One distinguishes provider and researcher experiences. Confirm the relevant deployment, permissions and data coverage directly. A public description of a capability is evidence that the company offers or describes it; it does not establish that every institution already has it enabled or that the same terms apply in every geography.

07 / DecisionStart with the evidence your intended decision requires

Tempus is worth evaluating when the desired workflow depends on connecting molecular and clinical evidence with research or institutional action. The first useful choice is the product route and evidence requirement, not the most impressive AI demonstration. A well-scoped evaluation should show where the information originates, what it permits the team to conclude and who remains responsible for the resulting work.